AU2001277549B2 - Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses - Google Patents

Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses Download PDF

Info

Publication number
AU2001277549B2
AU2001277549B2 AU2001277549A AU2001277549A AU2001277549B2 AU 2001277549 B2 AU2001277549 B2 AU 2001277549B2 AU 2001277549 A AU2001277549 A AU 2001277549A AU 2001277549 A AU2001277549 A AU 2001277549A AU 2001277549 B2 AU2001277549 B2 AU 2001277549B2
Authority
AU
Australia
Prior art keywords
groups
general formula
group
stands
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001277549A
Other languages
English (en)
Other versions
AU2001277549A1 (en
Inventor
Peter Mareski
Bernd Misselwitz
Ulrich Niedballa
Johannes Platzek
Bernd Raduchel
Hanns-Joachim Weinmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10040380A external-priority patent/DE10040380B4/de
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of AU2001277549A1 publication Critical patent/AU2001277549A1/en
Application granted granted Critical
Publication of AU2001277549B2 publication Critical patent/AU2001277549B2/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Request for Assignment Assignors: SCHERING AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001277549A 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses Ceased AU2001277549B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10040380.8 2000-08-11
DE10040380A DE10040380B4 (de) 2000-08-11 2000-08-11 Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
PCT/EP2001/008498 WO2002013874A2 (de) 2000-08-11 2001-07-23 Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen

Publications (2)

Publication Number Publication Date
AU2001277549A1 AU2001277549A1 (en) 2002-05-23
AU2001277549B2 true AU2001277549B2 (en) 2007-02-08

Family

ID=7652860

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001277549A Ceased AU2001277549B2 (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
AU7754901A Pending AU7754901A (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU7754901A Pending AU7754901A (en) 2000-08-11 2001-07-23 Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses

Country Status (26)

Country Link
EP (1) EP1307236A2 (ko)
JP (1) JP2004506025A (ko)
KR (1) KR20030022387A (ko)
CN (1) CN1469757A (ko)
AR (1) AR034139A1 (ko)
AU (2) AU2001277549B2 (ko)
BG (1) BG107542A (ko)
BR (1) BR0113188A (ko)
CA (1) CA2419223A1 (ko)
CZ (1) CZ2003392A3 (ko)
DE (1) DE10066210B4 (ko)
EE (1) EE200300061A (ko)
HR (1) HRP20030173A2 (ko)
HU (1) HUP0300736A3 (ko)
IL (1) IL154385A0 (ko)
MX (1) MXPA03001287A (ko)
NO (1) NO20030604L (ko)
NZ (1) NZ523932A (ko)
PL (1) PL365596A1 (ko)
RU (1) RU2290206C2 (ko)
SK (1) SK1572003A3 (ko)
TW (1) TWI296931B (ko)
UA (1) UA82642C2 (ko)
WO (1) WO2002013874A2 (ko)
YU (1) YU10603A (ko)
ZA (1) ZA200301949B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344704B2 (en) 2002-07-10 2008-03-18 Schering Ag Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
DE10231799B4 (de) * 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
US7887835B2 (en) * 2006-09-19 2011-02-15 Fujifilm Corporation Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound
DE102006049821A1 (de) * 2006-10-18 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Metallchelate mit perfluoriertem PEG-Rest, Verfahren zu deren Herstellung, sowie deren Verwendung
DE102007015598A1 (de) * 2007-03-29 2008-10-02 Heinrich-Heine-Universität Düsseldorf Verwendung von fluorhaltigen Verbindungen zu Diagnosezwecken mit Hilfe bildgebender Verfahren
JP2011190183A (ja) * 2010-03-11 2011-09-29 Noguchi Institute フルオラス化糖結合型クラウンエーテル誘導体
US9976072B2 (en) 2014-03-26 2018-05-22 Chevron U.S.A. Inc. Multicarboxylate compositions and method of making the same
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
CN109715597A (zh) * 2016-09-14 2019-05-03 大金工业株式会社 含支链含氟化合物
CN110035996B (zh) 2016-11-28 2022-08-09 拜耳医药股份公司 用于磁共振成像的新型高弛豫性钆螯合物
PE20211471A1 (es) 2018-11-23 2021-08-05 Bayer Ag Formulacion de medios de contraste y proceso para prepararlos
CN109867635A (zh) * 2019-02-14 2019-06-11 华东师范大学 一种t1型胶束磁共振成像造影剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
AU715788B2 (en) * 1996-10-07 2000-02-10 Nec Corporation Power supply switching circuit with protection function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19603033A1 (de) * 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19729013A1 (de) * 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715788B2 (en) * 1996-10-07 2000-02-10 Nec Corporation Power supply switching circuit with protection function
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis

Also Published As

Publication number Publication date
DE10066210B4 (de) 2008-02-28
RU2290206C2 (ru) 2006-12-27
EE200300061A (et) 2004-12-15
HRP20030173A2 (en) 2005-04-30
NO20030604D0 (no) 2003-02-07
SK1572003A3 (en) 2003-10-07
EP1307236A2 (de) 2003-05-07
WO2002013874A8 (de) 2002-06-13
BR0113188A (pt) 2003-06-24
PL365596A1 (en) 2005-01-10
NO20030604L (no) 2003-04-11
AU7754901A (en) 2002-02-25
IL154385A0 (en) 2003-09-17
KR20030022387A (ko) 2003-03-15
JP2004506025A (ja) 2004-02-26
CN1469757A (zh) 2004-01-21
HUP0300736A3 (en) 2010-01-28
BG107542A (bg) 2003-09-30
MXPA03001287A (es) 2003-10-06
ZA200301949B (en) 2004-12-14
HUP0300736A2 (hu) 2003-09-29
CA2419223A1 (en) 2003-02-11
YU10603A (sh) 2006-05-25
AR034139A1 (es) 2004-02-04
WO2002013874A2 (de) 2002-02-21
UA82642C2 (uk) 2008-05-12
CZ2003392A3 (cs) 2003-09-17
NZ523932A (en) 2007-07-27
TWI296931B (en) 2008-05-21

Similar Documents

Publication Publication Date Title
AU2001277549B2 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
US20060093554A1 (en) Galenical formulations
US6818203B2 (en) Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
AU2001289729B2 (en) Perfluoroalkyl-containing complexes comprising sugar residues, method for producing the same and use thereof
US20090297454A1 (en) Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use
BRPI0613407A2 (pt) Complexos contendo perfluoralquila, bem como composição farmacêutica, uso e processos de preparação dos mesmos
US6641797B2 (en) Perfluoroalkyl-containing complexes with sugar radicals, process for their production and their use
ZA200108575B (en) Perfluoroalkylamide, the production thereof and the use thereof in diagnostics.
AU2001279777B2 (en) Complexes containing perfluoroalkyl with polar radicals, method for the production and use thereof
US6676928B2 (en) Perfluoroalkyl-containing complexes with polar radicals, process for their production and their use
JP2000514850A (ja) プソイドポリロタキサン
US6461587B1 (en) Perfluoroalkylamides, their production and their use in diagnosis
SG177994A1 (en) Metal chelates having a perfluorinated peg group, method for the production thereof, and use thereof
DE10040380A1 (de) Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques, Tumoren und Nekrosen
US7344704B2 (en) Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi
KR20050017095A (ko) 혈관내 혈전을 나타내기 위한 자기 공명 영상화에서의조영제로서 퍼플루오로알킬 함유 금속 착물의 용도

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: FORMER NAME: SCHERING AG

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired